key: cord-0278292-smg0j5ld authors: Ronchini, C.; Gandini, S.; Pasqualato, S.; Mazzarella, L.; Facciotti, F.; Mapelli, M.; IEO Covid Team,; Frige', G.; Passerini, R.; Pase, L.; Capizzi, S.; Mastrilli, F.; Orecchia, R.; Natoli, G.; Pelicci, P. G. title: Lower probability and shorter duration of infections after Covid-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs date: 2021-09-27 journal: nan DOI: 10.1101/2021.09.24.21263978 sha: 3197ad894fef1e7ebd24cecfd4566d3861ed3a67 doc_id: 278292 cord_uid: smg0j5ld The correlation between immune responses and protection from SARS-CoV-2 infections and its duration remains unclear. We performed a sanitary surveillance at the European Institute of Oncology (IEO) in Milan over a 27 months period. Pre-vaccination, in 1493 participants, we scored 266 infections (17.8%) and 8 possible reinfections (3%). Post-vaccination, we identified 30 infections in 2029 vaccinated individuals (1.5%). We report that the probability of infection post-vaccination is i) significantly lower compared to natural infection, ii) associated with a significantly shorter median duration of infection than that of first infection and reinfection, iii) anticorrelated with circulating antibody levels. SARS-CoV-2 pandemic has resulted in more than 220 million infections and 4.5 million deaths worldwide (Worldometer COVID-19 coronavirus pandemic. https://www.worldometers.info/coronavirus). SARS-CoV-2 vaccination induces strong humoral [1, 2] and cellular [3] immunity and its high effectiveness has been shown in different contexts and populations [4] [5] [6] [7] [8] [9] . We performed systematic sanitary surveillance of the personnel working at the European Institute of Oncology (IEO), a large comprehensive cancer center in Milan, Northern Italy. Starting from April 2020, all workers, including health-care, support staff, administrative and research personnel, were tested for SARS-CoV-2 infection by quantitative PCR (qPCR) detection of viral genes, using the Allplex SARS-CoV-2 Assay (Seegene) on nasopharyngeal or saliva samples. Humoral immunity was measured by testing levels of IgGs against the receptor binding domain (RBD) of the spike protein using an in-house ELISA assay [10]. 1,493 participants were initially enrolled into the study starting from April 2020 and monitored before the vaccination campaign, which started on January 7 th , 2021. 2,029 individuals, including the first cohort, were then vaccinated and monitored until June 2021 (characteristics of our study cohorts are reported in Table S1 ; timing of tests is described in Supplementary materials -'Procedures' section and Supplementary Figure 1 ). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint In the pre-vaccination phase of our screening, we detected 266 SARS-CoV-2 infections (17.8%, 266/1,493). Multivariate logistic models were used to identify independent variables associated with infections during follow-up. While age, COVID-19-symptoms pre-study or a positive PCR-test at baseline did not show significant association, nurse/physician vs. other professionals (researchers, technicians, administratives) were highly correlated with increased probability of infection (P<0.0001). Notably, subjects that were IgG+ at the time of enrollment (T0; Supplementary Figure S2 ) had 66% significantly lower probability of having a positive swab (OR=0.34, 95%CI: 0.14-0.80, P=0.014, Supplementary Table S4) . We also observed 8 putative re-infections (8/266; ~3%) (Supplementary Table S2 ). Re-infections were defined as two PCR-positive samples interspersed with >1 PCR-negative sample. 5 individuals (all IgG+) had reinfection at >60 days. 7 of the 8 re-infected subjects were IgG+ at the time of enrollment (T0; Supplementary Figure S2 ). Frequency of re-infection with respect to the status of IgG at time of enrollment was ~9% (7/80) in the IgG+ and 25% (1/4) in the IgG-subjects (difference is not statistically significant, Fisher exact test P=0.335; Table 2 ). 6 (4/5 IgG+) showed qPCR-positivity to only 1 of the 3 viral-genes tested and with Ct cycles >30. When considering only individuals testing positive for more than one SARS-CoV-2 gene in the PCR assay, frequencies of re-infection decreased significantly (2/266, <1%; 3% vs 0% for IgG+ vs IgG-). 2,029 subjects were tested post-vaccination with the Pfizer BNT162b2 or Astra Zeneca (AZ) vaccines. 90% subjects completed the two doses of BNT162b2, and 181 received a single or double dose of AZ. We observed a high rate of vaccination effectiveness, as measured by circulating anti-SARS-CoV-2 RBD IgGs 1 week post-vaccination, with: i) high antibody levels in the entire population (median ~5 fold increased over the threshold; min=1 and max=12.5) and across each age-group (age range: 19-81y/o); and ii) only 1.9% (39/2,029) of non-responders (IgG levels <0.28) ( Figure 1 ). IgG levels inversely correlated with age, with the lowest levels (median of 7.9) in . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table S3 and Figure 2 ). Moreover, to our knowledge, all infected individuals reported asymptomatic or pauci-symptomatic infections. The frequency of molecularly detectable infections among the IgG+ vaccine-responders (subjects that positively responded to vaccination) was significantly lower (1,4%) than in the IgG+ nonvaccinated subjects after natural infection (9%; P=0.0002) and the IgG-vaccine non-responders (5.7%; P=0.042) ( Table 2) . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Among the newly infected vaccinated-subjects, 3 cases were IgG non-responders (IgG-). Notably, the remaining 27 infected vaccinated individuals were mainly distributed in the lower quartiles of anti-RBD antibody titers (~74% in quartiles 1 and 2; Table 1B and Figure 1 ). Large longitudinal cohort studies with regular testing are needed to provide systematic epidemiological, virological, immunological, and clinical data useful to understand the rates of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2021. ; https://doi.org/10.1101/2021.09.24.21263978 doi: medRxiv preprint reinfection and their implications for health policies. Moreover, data presented in this study will need to be updated to estimate the impact of the delta variant on reinfection/post-vaccine infection risk, considering that the delta variant was not diffuse in our country at the time of testing described in our study. Overall, our data show that individuals who responded to vaccination based on the detection of anti- We thank Fondazione Europea Guido Venosta, National Instruments Corporation, Ralph Lauren and Fondo MFS for funding this research and Fondazione IEO-CCM for fund-raising. The authors declare no conflict of interest . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2021. Immunity to SARS-CoV-2 induced by infection or vaccination The immunology of SARS-CoV-2 infections and vaccines Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting